Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical context.Using an observational database from 169 hospitals in Asia, Europe, and North America, we evaluated the relationship of cardiovascular disease and drug (...) to 1.74).Our study confirmed previous observations suggesting that underlying cardiovascular disease is associated with an increased risk of in-hospital death among patients hospitalized with Covid-19. Our results did not confirm previous concerns regarding a potential harmful association of ACE inhibitors or ARBs with in-hospital death in this clinical context. (Funded by the William Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women's Hospital.).Copyright © 2020

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS).To determine whether switching to ticagrelor monotherapy after 3 (...) with ticagrelor-based 12-month DAPT (HR, 0.56 [95% CI, 0.34 to 0.91]; P = .02). The incidence of major adverse cardiac and cerebrovascular events was not significantly different between the ticagrelor monotherapy after 3-month DAPT group (2.3%) vs the ticagrelor-based 12-month DAPT group (3.4%) (HR, 0.69 [95% CI, 0.45 to 1.06]; P = .09).Among patients with acute coronary syndromes treated with drug-eluting stents, ticagrelor monotherapy after 3 months of dual antiplatelet therapy, compared with ticagrelor

Maternal cardiovascular risk after hypertensive disorder of pregnancy Maternal Cardiovascular Risk After Hypertensive Disorder of Pregnancy - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged (...) Actions . 2020 May 13;heartjnl-2020-316541. doi: 10.1136/heartjnl-2020-316541. Online ahead of print. Maternal Cardiovascular Risk After Hypertensive Disorder of Pregnancy , , , , , , , , Affiliations Expand Affiliations 1 Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. 2 Cardiometabolic, George Institute for Global Health, Sydney, New South Wales, Australia. 3 Sydney Medical School, University of Sydney, Sydney, NSW, Australia. 4 Medicine, University of New South Wales

Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Apr 28;dc192116. doi: 10.2337/dc19-2116. Online ahead of print. Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study , , , , , , , , , , Affiliations Expand Affiliations

Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic - American College of Cardiology ') Search All Types Search or Menu . This article was authored by Nicole M. Orr, MD, FACC , and the Geriatric Cardiology Council. Share via: Clinical Topics: Keywords: Aged, SARS Virus, Angiotensin Receptor Antagonists (...) , Hydroxychloroquine, Mineralocorticoid Receptor Antagonists, Caregivers, Angiotensin-Converting Enzyme Inhibitors, COVID-19, Coronavirus, Coronavirus Infections, Neprilysin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Neprilysin, Chloroquine, Subacute Care, Social Isolation, Skilled Nursing Facilities, Cardiovascular Diseases > > Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic Heart House 2400 N Street NW Washington, DC 20037 Phone: , ext

Covid-19 and cardiovascular disease. Guideline: Diagnosis and management of cardiovascular disease during the covid-19 pandemicPublished by the European Society of Cardiology.This summary is based on the version published on 21 April 2020 (https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance).Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing

Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Some studies, mainly from high-income countries (HICs), report that women receive less care (investigations and treatments) for cardiovascular disease than do men and might have a higher risk of death. However, very few studies systematically report risk factors, use of primary or secondary (...) prevention medications, incidence of cardiovascular disease, or death in populations drawn from the community. Given that most cardiovascular disease occurs in low-income and middle-income countries (LMICs), there is a need for comprehensive information comparing treatments and outcomes between women and men in HICs, middle-income countries, and low-income countries from community-based population studies.In the Prospective Urban Rural Epidemiological study (PURE), individuals aged 35-70 years from urban

. Med. 2017; 167 : Itc81-itc96 World Health Organization. The World Health Report 2002: Quantifying Selected Major Risks to Health2002:49-97. Halcox J.P. Banegas J.R. Roy C. et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc. Disord. 2017; 17 : 160 Zwald ML, Akinbami LJ, Fakhouri TH, Fryar CD. Prevalence of Low High-density Lipoprotein Cholesterol Among Adults (...) of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc. Disord. 2014; 14 : 121 Sabatine M.S. Giugliano R.P. Keech A.C. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N. Engl. J. Med. 2017; 376 : 1713-1722 Article Info Publication History Accepted: March 17, 2020 Received in revised form: February 28, 2020 Received: November 4, 2019 Publication stage In Press Journal Pre-Proof Identification DOI: Copyright © 2020 Published by Elsevier Inc

Position Statement on Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic 1 Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement by the Cardiac Society of Australia and New Zealand Stephen J Nicholls 1 , Mark Nelson 2 , Carolyn Astley 3 , Tom Briffa 4 , Alex Brown 5 , Robyn Clark 3 , David Colquhoun 6 , Robyn Gallagher (...) care across the world. In addition to the described cardiovascular disease (CVD) complications of COVID-19, including myocarditis, myocardial injury, arrhythmia and thromboembolism, the pandemic has additional implications for the management of the patient with established atherosclerotic CVD. In particular, it provides challenges for the use and introduction of secondary prevention measures. This position statement provides recommendations for effective delivery of secondary prevention strategies

Abstract Introduction: The Coronavirus-19 disease (COVID-19) pandemic is caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pre-existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID-19, and COVID-19 itself causes serious cardiac sequelae. Strategies to minimise the risk of viral transmission to healthcare workers and uninfected cardiac patients while prioritising high quality cardiac care are urgently needed. We conducted a rapid literature appraisal (...) 2 MI (28). Myocardial injury in COVID-19 patients can manifest with ST-elevation in the absence of obstructive coronary artery disease (CAD). Whether this is due to microvascular injury or myocarditis is unclear. To avoid unnecessary coronary angiography during the acute illness, haemodynamically stable patients with COVID-19 and possible MI may be best managed conservatively, with invasive procedures deferred until after COVID-19 recovery. Cardiovascular implications of novel therapies Numerous

Palliative Care Considerations For Patients With Cardiovascular Disease Under COVID-19 Palliative Care Considerations For Patients With Cardiovascular Disease Under COVID-19 - American College of Cardiology ') Search All Types Search or Menu CBT=cognitive behavioral therapy; IV=intravenous; po=by mouth; SL=sublingually + People with Parkinsonism, Lewy body disease or pre-existing cogwheel rigidity, for whom haloperidol is contraindicated, quetiapine 12.5-25 mg orally up to 4 times daily can (...) to the surge in deaths in most communities. Bereavement support and acknowledgement of both our loss as clinicians, and the family's loss should be routine after a death. Provider Resiliency The cardiovascular care team is immersed on the front lines preparing for the surge of COVID-19 patients or already deeply engaged depending on location. Usual stress and long hours have been superseded by novel adversaries. Clinicians work lacking PPE in a new environment, with risks of COVID-19 illness and mortality

SQC Approval Date: April 24, 2020 Patients with cardiovascular conditions, especially poorly controlled disease, are at higher risk for COVID-19 complications. As such, they should be counseled to avoid situations that would put them at risk for SARS CoV2 exposure. They, along with their physician, should evaluate their workplace and determine if undue risk exists. If so, mitigation strategies should be considered. These include minimizing face-to-face contact between employees, assigning work (...) Syndrome X, Angina, Stable, Heart Defects, Congenital, Dyslipidemias, Geriatrics, Heart Failure, Angiography, Diagnostic Imaging, Pericarditis, Secondary Prevention, Hypertension, Pulmonary, Sleep Apnea Syndromes, Sports, Angina, Stable, Exercise Test, Heart Valve Diseases, Aneurysm, COVID-19, Coronavirus, Coronavirus Infections, Cardiology Magazine, ACC Publications > > Feature | Key Questions on COVID-19 and Cardiovascular Disease Heart House 2400 N Street NW Washington, DC 20037 Phone: , ext. 5603

Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry) Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry) - PubMed This site needs JavaScript to work properly. Please enable (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 May 15;125(10):1500-1507. doi: 10.1016/j.amjcard.2020.02.028. Epub 2020 Mar 5. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical

problem of nomenclature that inhibited effective communication became apparent, and this contributed to mistaken diagnoses of POTS. One issue was that even within the expert panel, there was disagreement about whether POTS was a purely cardiovascular and hemodynamic disorder, or one that could be associated with other disorders with systemic (and nonhemodynamic) presentations. Some believed that if a patient had another condition (eg, Ehlers-Danlos syndrome) that they should not be diagnosed with POTS (...) Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance - Canadian Journal of Cardiology Go search , P357-372, March 01, 2020 Powered By Mendeley Share on Canadian Cardiovascular Society Position Statement on Postural Orthostatic

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis. Pooled phase 2 data suggest (...) favorable effects on clinical outcomes.To test whether apabetalone significantly reduces major adverse cardiovascular events.A randomized, double-blind, placebo-controlled trial, conducted at 190 sites in 13 countries. Patients with an acute coronary syndrome in the preceding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligible for enrollment, which started November 11, 2015, and ended July 4, 2018, with end of follow-up on July 3, 2019.Patients were

Associations of fat and carbohydrate intake with cardiovascular disease and mortality: prospective cohort study of UK Biobank participants. To investigate the association of macronutrient intake with all cause mortality and cardiovascular disease (CVD), and the implications for dietary advice.Prospective population based study.UK Biobank.195 658 of the 502 536 participants in UK Biobank completed at least one dietary questionnaire and were included in the analyses. Diet was assessed using

The use of statins in the primary prevention of cardiovascular disease: an online tool for shared-decision making 2019 www.kce.fgov.be KCE REPORT 324 THE USE OF STATINS IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: AN ONLINE TOOL FOR SHARED- DECISION MAKING 2019 www.kce.fgov.be KCE REPORT 324 HEALTH TECHNOLOGY ASSESSMENT THE USE OF STATINS IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: AN ONLINE TOOL FOR SHARED-DECISION MAKING CHRISTOPHE DE MEESTER (KCE), KARIN RONDIA (KCE), THOMAS (...) GOORDEN (LEF), SABINE JANSSENS (BSM), PIETER STEYAERT (TEMPERA), CHRIS DE LAET (KCE), MICHEL ALBERTIJN (TEMPERA), LAURENCE KOHN (KCE) COLOPHON Title: The use of statins in the primary prevention of cardiovascular disease: an online tool for shared-decision making Authors: Christophe De Meester (KCE), Karin Rondia (KCE), Thomas Goorden (LEF), Sabine Janssens (BSM), Pieter Steyaert (Tempera), Chris De Laet (KCE), Michel Albertijn (Tempera), Laurence Kohn (KCE) Information specialist: Nicolas Fairon (KCE

disease prevention medications at least 80% of the time. The proportion of patients considered adherent increased by a median of 6.9 percentage points (an increase of ≈ 9.9%) The remaining 21 studies used various tools to measure adherence (e.g., objective provider counts or records, self-report) and reported generally favorable results. Cardiovascular Disease Risk Conditions A subset of 17 studies evaluated intervention effects on blood pressure control and lipid control. There was a median increase (...) " or "cardiovascular diseases").mp. 33. ("cerebrovascular disease" or "cerebrovascular diseases" or "cerebrovascular event" or "cerebrovascular events" or "angina" or "coronary disease" or "coronary artery disease" or "ischemia" or "myocardial ischemic preconditioning").mp. 34. ("transient ischemic attack" or "brain hypoxia ischemia" or "myocardial ischemia" or "heart diseases" or "myocardial infarction" or "stroke" or "cerebrovascular disorders" or "basal ganglia cerebrovascular disease").mp. 35. (angina pectoris

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower lipoprotein(a) levels.We conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol (...) 0.003 to <0.001). There were no significant differences between any APO(a)-LRx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms. The most common adverse events were injection-site reactions.APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. (Funded by Akcea Therapeutics; ClinicalTrials.gov number, NCT03070782.).Copyright © 2020

Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. To examine how a healthy lifestyle is related to life expectancy that is free from major chronic diseases.Prospective cohort study.The Nurses' Health Study (1980-2014; n=73 196) and the Health Professionals Follow-Up Study (1986-2014; n=38 366).Five low risk lifestyle factors: never smoking, body mass index 18.5-24.9, moderate to vigorous physical activity (≥30 minutes (...) /day), moderate alcohol intake (women: 5-15 g/day; men 5-30 g/day), and a higher diet quality score (upper 40%).Life expectancy free of diabetes, cardiovascular diseases, and cancer.The life expectancy free of diabetes, cardiovascular diseases, and cancer at age 50 was 23.7 years (95% confidence interval 22.6 to 24.7) for women who adopted no low risk lifestyle factors, in contrast to 34.4 years (33.1 to 35.5) for women who adopted four or five low risk factors. At age 50, the life expectancy free